Plasma neurofilament light for early differentiation of multiple system atrophy from Parkinson disease
Plasma NfL may support the differentiation between clinically diagnosed MSA and PD, including early in the disease course, and the limited added value of multimarker panels supports a simpler and more immediately translatable NfL-first strategy for diagnostically uncertain parkinsonism.